PTEN (Ab-380/382/383) Antibody

What is PTEN (Ab-380/382/383) Antibody and what epitope does it specifically recognize?

PTEN (Ab-380/382/383) Antibody is a polyclonal antibody typically raised in rabbits that specifically recognizes PTEN when phosphorylated at serine 380, threonine 382, and threonine 383 residues. The immunogen used to produce this antibody is a synthetic peptide sequence around amino acids 378-385 (R-Y-S-D-T-T-D-S) derived from human PTEN, with phosphorylation at the specific serine and threonine residues . This C-terminal region is critical for regulating PTEN's function through post-translational modifications.

The antibody is typically supplied in a buffered aqueous solution (phosphate buffered saline without Mg²⁺ and Ca²⁺, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol) at a concentration of approximately 1.0 mg/mL .

What is the molecular significance of PTEN phosphorylation at Ser380/Thr382/Thr383?

Phosphorylation of PTEN's C-terminal tail at Ser380, Thr382, Thr383, and Ser385 orchestrates multiple aspects of PTEN function:

• Structural regulation: Forms intramolecular interactions with PTEN's C2 and phosphatase domains, promoting a "closed" conformation

• Activity modulation: Generally reduces PTEN's phosphatase activity against phosphoinositides

• Localization control: Decreases PTEN membrane association, affecting access to PIP3 substrates

• Stability enhancement: Increases PTEN protein stability, protecting it from degradation

• Protein interaction changes: Alters PTEN's binding partners and signaling capabilities

Research using protein semisynthesis, NMR, X-ray crystallography, and computational simulations has revealed how the phospho-C-tail interacts with PTEN's domains. Crystal structures (PDB: 7JUK, 7JVX, 7JTX) provided at resolutions between 2.25 Å and 3.2 Å have elucidated these interactions at the atomic level .

What are the validated applications for PTEN (Ab-380/382/383) Antibody?

Based on multiple product specifications and research publications, this antibody has been validated for several applications:

The antibody has demonstrated reactivity with human, mouse, and rat samples, making it valuable for comparative studies across these species .

What sample preparation methods optimize detection of phosphorylated PTEN?

Proper sample preparation is critical for maintaining phosphorylation status and achieving optimal detection:

For Western blotting:

• Lyse cells in buffer containing phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate)

• Maintain samples at 4°C during processing

• Add protease inhibitors to prevent degradation

• Use fresh samples or flash-freeze and store at -80°C

• Include positive controls such as cells treated with EGF or PMA, which enhance PTEN phosphorylation

For immunohistochemistry:

• Fix tissues promptly in 10% neutral buffered formalin

• Perform heat-induced epitope retrieval (HIER) with citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Block endogenous peroxidase activity and non-specific binding

• Use blocking peptide controls to confirm specificity

For immunofluorescence:

• Methanol fixation has been demonstrated to be effective

• Include phosphatase inhibitors in all buffers

• Block with appropriate serum or BSA solution

• Consider confocal microscopy using a 60× oil objective for optimal visualization

How can researchers validate the specificity of PTEN (Ab-380/382/383) Antibody?

Rigorous validation ensures that observed signals truly represent phosphorylated PTEN:

• Phosphatase treatment control: Treat cell extracts with calf intestinal phosphatase (CIP) to eliminate antibody binding, confirming phospho-specificity

• Stimulation experiments: Treat cells with EGF or PMA to increase PTEN phosphorylation, enhancing signal intensity

• Blocking peptide competition: Pre-incubate antibody with phosphorylated immunizing peptide to eliminate specific staining

• Genetic controls: Use PTEN-null cells or PTEN knockdown samples as negative controls

• Cross-validation: Compare with other validated PTEN antibodies targeting different epitopes

• Mass spectrometry validation: Verify phosphorylation sites using phosphoproteomic analysis

Western blot analysis in search result demonstrates the specificity of this antibody, showing differential detection in extracts from cells treated with IFNα versus those treated with phosphatase, confirming its phospho-specificity.

What controls should be included when using this antibody in experiments?

A comprehensive experimental design should include several controls:

• Positive control: Samples known to have phosphorylated PTEN (e.g., cells treated with growth factors)

• Negative control: PTEN-deficient samples or phosphatase-treated samples

• Loading control: For Western blotting, include antibodies against housekeeping proteins

• Secondary antibody control: Omit primary antibody to assess secondary antibody background

• Treatment controls: For drug studies, include appropriate vehicle controls

• Total PTEN control: Always examine total PTEN levels in parallel using a phosphorylation-independent antibody

What are common issues when using PTEN (Ab-380/382/383) Antibody and how can they be resolved?

Storage recommendations include keeping the antibody at -20°C or -80°C and avoiding repeated freeze-thaw cycles .

How does PTEN (Ab-380/382/383) Antibody performance compare to immuno-MRM approaches for PTEN quantification?

Recent advances in PTEN detection methodologies include immuno-MRM (iMRM):

• iMRM provides precise quantitation of PTEN concentrations down to 0.1 fmol/10 μg of extracted protein

• iMRM has demonstrated high interday and intraday precision (CV 6.3%)

• iMRM can detect PTEN in samples deemed PTEN-negative by IHC or Western blot

• iMRM requires substantially less tissue than Western blotting

• iMRM provides actual protein concentrations rather than arbitrary intensity values, facilitating cross-laboratory comparisons

• An 11-minute microflow LC-MRM analysis on a triple-quadrupole MS can be used for standardized workflows

While antibody-based detection remains the standard for analyzing phosphorylation at specific sites, complementary approaches like iMRM offer advantages for precise total PTEN quantification.

How can PTEN (Ab-380/382/383) Antibody be used to study cancer mechanisms and treatment responses?

The antibody enables sophisticated experimental designs to elucidate cancer mechanisms:

• Signaling network mapping: Combine with antibodies against other phosphorylated proteins in the PI3K/AKT/mTOR pathway to examine pathway activation

• Patient stratification: Correlate phosphorylated PTEN status with clinical outcomes and treatment responses

• Drug resistance studies: Investigate whether altered PTEN phosphorylation contributes to resistance to PI3K/AKT/mTOR inhibitors

• Biomarker development: Integrate phosphorylated PTEN status into multi-parameter biomarker panels for cancer diagnosis and prognosis

• Tumor heterogeneity analysis: Examine spatial variation in PTEN phosphorylation within tumors

Research has shown a potential inverse correlation between PTEN expression levels and HER2-Tyr1221/1222 phosphorylation (r² = 0.9597), which is an established measure of HER2 receptor activity . This relationship could be further explored using PTEN (Ab-380/382/383) Antibody to assess whether PTEN phosphorylation status might serve as a predictive biomarker for anti-HER2 therapy.

What emerging approaches integrate PTEN phosphorylation data into broader cancer genomics?

Researchers are developing integrated approaches to contextualize PTEN phosphorylation data:

• Multi-omics integration: Correlating phosphorylated PTEN levels with genomic, transcriptomic, and proteomic profiles

• Patient-derived models: Analyzing phosphorylated PTEN in PDX models, organoids, or primary cultures

• Liquid biopsies: PTEN status in circulating tumor cells (CTCs) may serve as a non-invasive biomarker, with CTC PTEN FISH assays being employed in clinical trials

• AI-based image analysis: Applying machine learning to identify patterns in phosphorylated PTEN distribution that correlate with outcomes

• Proteogenomic analysis: Combining PTEN gene copy number and mutation data with phosphorylation status

Studies have shown that PTEN protein levels do not always correlate with gene copy number, emphasizing that "genome-only analyses may often not be sufficient to capture the phenotype of a tumor and to make optimal treatment decisions" .

How does PTEN (Ab-380/382/383) Antibody contribute to understanding PTEN mutations in disease?

This antibody can help characterize how disease-associated mutations affect PTEN phosphorylation:

• Mutation impact studies: Examine how PTEN mutations affect phosphorylation at Ser380/Thr382/Thr383

• Protein stability analysis: Investigate whether mutations alter the stabilizing effect of phosphorylation

• Structure-function relationships: Determine if mutations disrupt intramolecular interactions involving the phosphorylated C-tail

• Functional consequences: Assess how phosphorylation influences the activity of PTEN mutants

For example, study identified a PTEN mutation (c.302T>C resulting in I101T) in a patient with intellectual disability, revealing reduced protein stability as one mechanism responsible for decreased PTEN activity. Phospho-specific antibodies could help determine whether alterations in phosphorylation contribute to this instability.

What novel methodologies are enhancing the utility of PTEN phosphorylation analysis?

Several cutting-edge approaches are expanding how researchers can study PTEN phosphorylation:

• CRISPR/Cas9 screens: Genome-wide screens can identify genes affecting PTEN phosphorylation status

• Single-cell analysis: Examining phosphorylated PTEN at the single-cell level to understand heterogeneity within populations

• Phosphoproteomics: Mass spectrometry-based approaches to globally profile phosphorylation changes

• Nanobody development: Creating smaller antibody fragments for improved tissue penetration and live-cell imaging

• Optogenetic tools: Controlling PTEN phosphorylation with light to study temporal dynamics

• Multiplexed imaging: Simultaneously visualizing multiple phosphorylation sites and signaling molecules

How might PTEN (Ab-380/382/383) Antibody be incorporated into clinical diagnostic workflows?

While primarily a research tool, this antibody has potential applications in precision medicine:

• Standardized IHC protocols: Development of validated clinical assays for phosphorylated PTEN detection

• Companion diagnostics: Identifying patients likely to respond to PI3K/AKT/mTOR pathway inhibitors

• Treatment monitoring: Assessing changes in PTEN phosphorylation during therapy

• Resistance mechanisms: Identifying altered phosphorylation as a potential resistance mechanism

• Combined biomarker panels: Integrating phosphorylated PTEN status with other molecular markers

The specific detection of PTEN protein, including its phosphorylated forms, could serve as a biomarker parameter in clinical oncology to guide therapeutic decisions. This requires using "highly defined anti-PTEN monoclonal antibodies, characterized with precision in terms of sensitivity for the detection technique, specificity for PTEN binding, and constraints of epitope recognition" .